Intelligence IAMay 4, 2026Primary Market
Article
EnteroBiotix · £19M · Series Unknown
EnteroBiotix has secured £19 million in funding to support a clinical trial for microbiome-based therapies targeting irritable bowel syndrome. The company is based in Glasgow.
Redaction Data Cube AISource: Unknown
01
Brief source
EnteroBiotix has secured £19 million in funding to support a clinical trial for microbiome-based therapies targeting irritable bowel syndrome. The company is based in Glasgow.